SciClone Could Pay SEC $12.8 Million in FCPA Case
SciClone Pharmaceuticals has disclosed in a quarterly report that it’s discussing a tentative $12.8 million settlement with the Securities and Exchange Commission to resolve an investigation of potential violations of the Foreign Corrupt Practices Act with respect to its China operations. Details inside.
Related articles
-
WebcastSept 23 | Decoding DOJ’s Recent Guidance on FCPA Enforcement
Join this timely and practical webinar as we break down the DOJ’s latest FCPA guidance and explore what these developments mean for compliance programs in the real world.
-
ArticleProsecutions of bribery, health fraud and market tampering are DOJ top priorities
Serious bribery, health care fraud and crimes that threaten U.S. investors are top enforcement priorities of the Trump Department of Justice, (DOJ), according to the acting head of the Department of Justice’s Criminal Division.
-
ArticleFormer U.S. clothing business CEO faces 25 years for bribery in Honduras
The former CEO of a Georgia clothing business faces 25 years in prison for bribing Honduran officials to win $10 million in uniform contracts in Honduras, after being caught up in a Department of Justice Anticorruption Task Force.